Arborgen Holdings Limited · NZX:ARB
Arborgen — Shareholder Meeting (September 2026)
24 slides from Arborgen's shareholder meeting presentation, Sep 15, 2026
Slide 1: Annual Shareholders' Meeting
ANNUAL SHAREHOLDERS’ MEETING 15 September 2026 ArborGen 2026 ASM 1
Slide 2: Introducing the Board
INTRODUCING THE BOARD David Knott – Chairman George Adams – Independent Director Appointed 19 August 2021 Appointed 12 August 2019 Standing for re-election Paul Smart – Independent Director Thomas Avery – Independent Director Ozey Horton – Independent Director Appointed 21 August 2018 Appointed 18 J
Slide 3: Chair of the Board
CHAIR OF THE BOARD David Knott ArborGen 2026 ASM
Slide 4: Lookback Regional Markets
LOOKBACK REGIONAL MARKETS Sale of ANZ business in FY22 → focus on US South and Sales Revenue Brazil US $m 80 70 Brazil 60 • Rapid expansion, growing pains now being addressed 50 • Opportunity: Large and growing market with 40 increasing demand for higher quality seedlings 30 20 US South 10 • Market
Slide 5: FY26 Performance Snapshot
FY26 PERFORMANCE SNAPSHOT Sales Volume and Revenue US $m 360m 375m 369m 328m 324m 67.7 63.2 68.2 • Record revenue result – supported by higher 47.5 56.1 average selling prices • Adjusted US GAAP EBITDA up 31% YOY, despite weakness in US market FY22 FY23 FY24 FY25 FY26 • Earnings increased ahead of r
Slide 6: Margins Reflect Growth and Market Cycle
MARGINS REFLECT GROWTH AND MARKET CYCLE Growth investments made → platform for significant operating leverage FY22 – FY26: Investment into growth opportunity in Brazil Gross Margin % (US GAAP) FY26 margins reflect: • Lower US volumes + under-utilised capacity Investment in growth initiatives • Brazi
Slide 7: Capital Management
CAPITAL MANAGEMENT Increase in borrowings reflects investment in growth FY22 – 26: Invested substantially to grow the business Net Debt and Cash Generation Net debt post-HQ sale – expansion of production capacity in Brazil, higher Investment in growth 25.2 value genetics, container seedlings 20.9 Ac
Slide 8: Shareholder Value
SHAREHOLDER VALUE Maximise value for all shareholders • Focus on converting potential into stronger earnings, cash flow and returns • Continue to assess portfolio, capital allocation and opportunities to realise greater value • Remain open to strategic proposals Share price and liquidity • Challenge
Slide 9: Strategic Progress and Next Steps
STRATEGIC PROGRESS AND NEXT STEPS FY22 – FY25 FY26 – FY27 FY28 onwards Reshape and Invest for Growth Strengthen Extract Value ✓ Sale of ANZ • High value sales mix: accelerate • Profitable growth in Brazil ✓ Exit out of pandemic sales, adoption and development of • Optimise US returns disruption adva
Slide 10: FY27 Outlook
FY27 OUTLOOK ArborGen is entering FY27 with a stronger operational platform, a more resilient business For FY27, ArborGen is targeting continued improvement in revenue, cash generation and debt reduction and clear opportunities for growth. • Continued volume growth in Brazil, supported by increased
Slide 11: Positioned to Perform
POSITIONED TO PERFORM • Clear strategy • Market leadership position in target markets - US South and Brazil • Unparalleled product portfolios in each of our core markets • Focused on value growth • Multi-decade investment in research and intellectual property • Service more than 2,000 customers each
Slide 12: Interim CEO
INTERIM CEO Patrick Cumbie ArborGen 2026 ASM
Slide 13: Leadership Focus 2026
LEADERSHIP FOCUS 2026 Strategic Build sales of high value Expand Cash generation and Priorities products margins debt reduction LEADERSHP PRIORITIES People and Culture Strong management. Committed and passionate team. Experts in our field. Customer focused. Genetics Leadership Leverage our strengths
Slide 14: The Genetics Dividend
THE GENETICS DIVIDEND Genetically Superior Trees Superior Trees Straighter, higher value, more disease resistance, increased harvest Genetically Improved Seedlings Offspring with enhanced traits from seed orchards Seed Orchards Controlled environments where selected parent trees produce improved see
Slide 15: Smarter Seedlings. Clearer Choices.
SMARTER SEEDLINGS. CLEARER CHOICES. PRODUCT CATEGORIES ARBORGEN SCORE Volume Sawtimber Total ArborGen $/Acre at OP Reliable performance and Gain Potential Tons/Acre Score Clearcut balanced return OP Pro Improving productivity 15% 50% 190 60 $2,348 without added cost +$500/acre MCP Boosting sawtimber
Slide 16: Customers Are Realising Significant Gains
CUSTOMERS ARE REALISING SIGNIFICANT GAINS Total Volume by Age with Genetic Trends 200 • Significant hectares of commercial Total Volume (tons/acre) MCP plantations are now reaching 150 mid-rotation ages Genetics MCP-Pro+ • Real-world data is being captured 100 OP and customers are seeing solid gains
Slide 17: Protected Eucalyptus Clones Offer Exceptional Yield Gains
PROTECTED EUCALYPTUS CLONES OFFER EXCEPTIONAL YIELD GAINS Protected eucalyptus clones offer exceptional yield gains over market clones in Brazil • We test and evaluate licensed and proprietary genetics for the market across Brazil • Screened for propagation, growth, wood properties, diseases • Data
Slide 18: Market Opportunity
MARKET OPPORTUNITY Build scale in Brazil, grow market share in US South US SOUTH BRAZIL (Loblolly Pine) 1.35 BILLION 1.2b Eucalyptus 667 MILLION 150m Pine TOTAL MARKET Number of seedlings 543M ADDRESSABLE 720M MARKET 178M ARBORGEN CURRENT 119M VOLUME Market size and Addressable Market based on manag
Slide 19: Shareholder Discussion
SHAREHOLDER DISCUSSION ArborGen 2026 ASM 19
Slide 20: Resolutions
RESOLUTIONS Resolution 1: That the Directors be authorised to fix the fees and expenses of Grant Thornton as the Company’s auditor Resolution 2: Re-election of Paul Smart as a Director of the Company Resolution 3: Re-election of Thomas Avery as a Director of the Company ArborGen 2026 ASM 20
Slide 21: Other Business / Close of the Meeting
OTHER BUSINESS CLOSE OF THE MEETING ArborGen 2026 ASM 21
Slide 22: 22
22
Slide 23: Adjusted US GAAP Reconciliation
ADJUSTED US GAAP RECONCILIATION Fiscal year ending March US $m Mar 1. Under US GAAP, from a statutory reporting perspective, the classification of the expense items, and other significant items in this table may differ from what is 2026 presented in the financial statements. US GAAP 2. US GAAP EBITD
Slide 24: Disclaimer
DISCLAIMER This presentation has been prepared by ArborGen Holdings Limited (“ArborGen”), to provide an overview of the performance of ArborGen and its activities at the date of this presentation. It is not prepared for any other purpose and must not be provided to any person other than the intended
ArborGen Holdings — Shareholder Meeting (September 2026) on 6ix